Featured Press Releases

Kashiv BioSciences Announces Positive Topline Results from the Confirmatory Efficacy Study of ADL-018, a Biosimilar Candidate to XOLAIR® (omalizumab).

Kashiv BioSciences Announces Positive Topline Results from the Confirmatory Efficacy Study of ADL-018, a Biosimilar Candidate to XOLAIR® (omalizumab).

Avenacy announces launch of Eptifibatide for Injection in the U.S.

Avenacy announces launch of Eptifibatide for Injection in the U.S.

  • 29 Apr 2024

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications,...

At AAD 2025, five-year data for BIMZELX® (bimekizumab-bkzx) demonstrated sustained skin clearance and long-term efficacy in moderate-to-severe plaque psoriasis

At AAD 2025, five-year data for BIMZELX® (bimekizumab-bkzx) demonstrated sustained skin clearance and long-term efficacy in moderate-to-severe plaque psoriasis

Viralgen Partners with Trogenix to Advance AAV Gene Therapy for Glioblastoma

Viralgen Partners with Trogenix to Advance AAV Gene Therapy for Glioblastoma

Bruker complements fast and cost-effective IR Biotyper® hospital hygiene testing and HAI tracing with NGS reflex testing

Bruker complements fast and cost-effective IR Biotyper® hospital hygiene testing and HAI tracing with NGS reflex testing

Dr. Behzad Mahdavi Has Been Appointed Executive Chairman of Biodextris to Lead Its Global Commercial Expansion

Dr. Behzad Mahdavi Has Been Appointed Executive Chairman of Biodextris to Lead Its Global Commercial Expansion

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

  • Spruce Biosciences, Inc.
  • 18 Aug 2025
Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

  • SystImmune, Inc.
  • 18 Aug 2025
New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

  • Genexa
  • 15 Aug 2025
Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

  • Daewoong Therapeutics Inc
  • 13 Aug 2025
Abcentra LLC Commences Phase 2b

Abcentra LLC Commences Phase 2b 'FORTIFY' Trial with First Patient Dosed, Evaluating Orticumab for Cardiovascular Disease

  • Abcentra
  • 12 Aug 2025
Viatris announces the approval of the first generic iron sucrose injection in the U.S

Viatris announces the approval of the first generic iron sucrose injection in the U.S

  • Viatris Inc.
  • 11 Aug 2025
Webinar: Leverage AI for Operational Excellence and Strategic Cost Management

Most Popular
August   2025
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.